Amy J Petty1, Lauren Floyd2, Christopher Henderson2, Matilda W Nicholas3. 1. School of Medicine, Duke University, Durham, NC, 27710, USA. 2. Department of Dermatology, Duke University, Durham, NC, 27710, USA. 3. Department of Dermatology, Duke University, Durham, NC, 27710, USA. Matilda.nicholas@duke.edu.
Abstract
PURPOSE OF REVIEW: The review provides an update on the diagnosis, pathogenesis, and treatment of cutaneous lupus erythematosus (CLE). RECENT FINDINGS: Diagnostic challenges exist in better defining CLE as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials. CLE is a group of complex and heterogenous diseases. Future studies are warranted to better define CLE within the spectrum of lupus erythematosus. Better insight into the pathogenesis of CLE could facilitate the design of more targeted therapies.
PURPOSE OF REVIEW: The review provides an update on the diagnosis, pathogenesis, and treatment of cutaneous lupus erythematosus (CLE). RECENT FINDINGS: Diagnostic challenges exist in better defining CLE as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials. CLE is a group of complex and heterogenous diseases. Future studies are warranted to better define CLE within the spectrum of lupus erythematosus. Better insight into the pathogenesis of CLE could facilitate the design of more targeted therapies.
Authors: Manfred Kunz; Inke R König; Arne Schillert; Jochen Kruppa; Andreas Ziegler; Harald Grallert; Martina Müller-Nurasyid; Wolfgang Lieb; Andre Franke; Annamari Ranki; Jaana Panelius; Sari Koskenmies; Taina Hasan; Juha Kere; Ann-Charlotte Rönn; Jan C Simon; Enno Schmidt; Joerg Wenzel; Thomas Tüting; Jennifer Landsberg; Tanja Zeller; Stefan Blankenberg; Regine Gläser; Nikolaos Patsinakidis; Annegret Kuhn; Saleh M Ibrahim Journal: Exp Dermatol Date: 2015-05-04 Impact factor: 3.960
Authors: Jorge A Irizarry-Caro; Carmelo Carmona-Rivera; Daniella M Schwartz; Sami S Khaznadar; Mariana J Kaplan; Peter C Grayson Journal: Arthritis Rheumatol Date: 2018-01-23 Impact factor: 10.995
Authors: A Kuhn; E Aberer; Z Bata-Csörgő; M Caproni; A Dreher; C Frances; R Gläser; H-W Klötgen; A Landmann; B Marinovic; F Nyberg; R Olteanu; A Ranki; J C Szepietowski; B Volc-Platzer Journal: J Eur Acad Dermatol Venereol Date: 2016-12-20 Impact factor: 6.166
Authors: Ferdinand Toberer; Jaromir Sykora; Daniel Göttel; Wolfgang Hartschuh; Siegfried Werchau; Alexander Enk; Stefan Joos; Peter H Krammer; Annegret Kuhn Journal: Exp Dermatol Date: 2013-10 Impact factor: 3.960
Authors: Cristina Drenkard; Sareeta Parker; Laura D Aspey; Caroline Gordon; Charles G Helmick; Gaobin Bao; S Sam Lim Journal: Arthritis Care Res (Hoboken) Date: 2019-01 Impact factor: 4.794
Authors: Richard Furie; Munther Khamashta; Joan T Merrill; Victoria P Werth; Kenneth Kalunian; Philip Brohawn; Gabor G Illei; Jorn Drappa; Liangwei Wang; Stephen Yoo Journal: Arthritis Rheumatol Date: 2017-02 Impact factor: 10.995
Authors: Alice Verdelli; Alberto Corrà; Elena Biancamaria Mariotti; Cristina Aimo; Valentina Ruffo di Calabria; Walter Volpi; Lavinia Quintarelli; Marzia Caproni Journal: Front Med (Lausanne) Date: 2022-09-23